نتایج جستجو برای: liraglutide

تعداد نتایج: 1699  

Journal: :Diabetes care 2015
Juris J Meier Julio Rosenstock Agnès Hincelin-Méry Christine Roy-Duval Astrid Delfolie Hans-Veit Coester Bjoern A Menge Thomas Forst Christoph Kapitza

OBJECTIVE This mechanistic trial compared the pharmacodynamics and safety of lixisenatide and liraglutide in combination with optimized insulin glargine with/without metformin in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination wit...

2017
Masao Toyoda Masaaki Miyauchi Noriko Kaneyama Moritsugu Kimura Tomoya Umezono Masafumi Fukagawa

Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese patients with type 2 diabetes. Material and Methods: This observational retrospective study included 47 patients with type 2 diabetes who were treated with liraglutide alone or...

2014
Chun-Jun Li Qian Yu Pei Yu Tie-Lian Yu Qiu-Mei Zhang Shan Lu De-Min Yu

BACKGROUND AND AIMS Liraglutide treatment can improve glycemic control with a concomitant weight loss, but the underlying mechanism on weight loss is not completely understood. Cardiac natriuretic peptides (NPs) can resist body fat accumulation through increasing adipocytes lypolysis. In this study, we tested the hypothesis that liraglutide-induced weight loss was associated with increased plas...

2012
Mitsuyoshi Takahara Toshihiko Shiraiwa Kentaro Ohtoshi Hideaki Kaneto Naoto Katakami Taka‐aki Matsuoka Iichiro Shimomura

UNLABELLED (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00223.x, 2012) Aims/Introduction:  We assessed the efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy (BOT). MATERIALS AND METHODS   We retrospectively analyzed the data of 37 patients who had postprandial hyperglycemia (≥10.0 mmol/L) with BOT (long-acting...

2017
A. Mehta S. P. Marso I. J. Neeland

OBJECTIVE To review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials. METHODS A search of the English language literature was performed using PubMed search terms: "liraglutide", "glucagon-like peptide-1 receptor agonist", and "randomized clinical trial". Articles and bibliographies relevant to the subject were reviewed and ad...

2014
Fiorenzo Santoleri Paola Sorice Ruggero Lasala Alberto Costantini

Introduction: Liraglutide and Exenatide are used in adults who are affected by type-2 diabetes to control their blood glucose level. They are administered by the patients by subcutaneous injection, Liraglutide once a day while Exenatide twice a day. The aim of this study was to evaluate medication adherence and persistence of treatment with Liraglutide and Exenatide with a new strategy of calcu...

Journal: :BBA clinical 2015
Marjolein K Sechterberger Jeroen Hermanides Rudolf W Poolman Jasper E Kal Joost C M Meijers Joost B L Hoekstra J Hans DeVries

BACKGROUND Hyperglycaemia during and after hip surgery is associated with coagulation activation and an increased risk of venous thromboembolism. Whether lowering of glucose levels during hip surgery diminishes coagulation activation is unknown. We investigated the efficacy of the human GLP-1 analogue liraglutide to lower glucose during and after hip surgery and studied its influence on coagula...

2013
Sara J. Micale Michael P. Kane Eileen Hogan

Liraglutide is a glucagon-like peptide 1 (GLP-1) analog indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. Liraglutide lowers blood glucose levels by stimulating insulin secretion and decreasing glucagon release in glucose-dependent manners, increases satiety, and delays gastric emptying. Liraglutide, unlike metformin and insulin, is not approv...

2015
Nan Lu Hanxiao Sun JingJia Yu Xiaojing Wang Dongmei Liu Lin Zhao Lihao Sun Hongyan Zhao Bei Tao Jianmin Liu Christian Holscher

Recently, a number of studies have demonstrated the potential beneficial role for novel anti-diabetic GLP-1 receptor agonists (GLP-1RAs) in the skeleton metabolism in diabetic rodents and patients. In this study, we evaluated the impacts of the synthetic GLP-1RA Liraglutide on bone mass and quality in osteoporotic rats induced by ovariectomy (OVX) but without diabetes, as well as its effect on ...

2016
J. Seufert T. Bailey S. Barkholt Christensen M. A. Nauck

This meta-analysis of seven randomized, placebo-controlled studies (total 3222 patients) evaluated whether type 2 diabetes (T2D) duration affects the changes in blood glucose control and body weight that can be achieved with liraglutide and placebo. With liraglutide 1.2 mg, shorter diabetes duration was associated with a significantly greater, but clinically non-relevant, difference in glycated...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید